Pfizer Acquires Rights to Alzheimer’s Drug
Sunday, September 7, 2008 - 16:49
in Health & Medicine
Pfizer said that it was acquiring the rights to Dimebon, a promising experimental drug for Alzheimer’s disease, from Medivation for as much as $725 million.